Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

Special Report

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

Clinical Forums Recaps

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Treatment Landscape Evolutions

Subscribe

Articles

The CHAI biomarker was shown to outperform EAU and AUA stratifications. 

CHAI biomarkers demonstrate prognostic utility for high-grade Ta NMIBC

Neckonoff is a graduating student of osteopathic medicine at New York Institute of Technology College of Osteopathic Medicine in New York, New York.

Benjamin P. Saylor is associate editor of Urology Times, an Advanstar Communications publication.

"Osteopathic urologists were more likely to work in private practice (58.4% vs 49.8%; P = .038) and in rural/nonmetropolitan areas (16.2% vs 8.7%; P = .002)," write the authors. 

Is there a difference between MD and DO in urology?

The results from the SABRE trial are intended to support the design of a registrational trial of 64Cu-SAR-Bombesin. 

64Cu-SAR-Bombesin shows efficacy in detecting prostate cancer recurrence

Benjamin M. Brucker, MD, discusses best practices for the onabotulinumtoxinA procedure, spanning all phases of treatment—before, during, and after administration.

From prep to follow-up: Key considerations for administering onabotulinumtoxinA

The prostate cancer section is a comprehensive resource for urology news and expert insights. Read more at Urology Times.

Prostate Cancer | Urology News & Expert Insights | Urology Times

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times – News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

Clinical Focus

Leonard G. Gomella, MD, FACS; Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MD

18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies

Pearls & Perspectives, with Amy Pearlman, MD

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

, host Amy Pearlman, MD, sits down with Helen Bernie, DO, MPH, at the 

American Urological Association's (AUA) 2025 Annual Meeting

 in Las Vegas for an in-depth discussion on some of the biggest questions facing men’s health and urology today.

Bernie, Director of Male Sexual and Reproductive Medicine at Indiana University, discusses her team’s impressive research output, including 10 abstracts presented at AUA. She offers an inside look at the year-long, collaborative process behind their studies, emphasizing the critical role of dedicated research fellows, medical students, and multi-institutional collaborations.

The conversation shifts to  research on the safety of testosterone therapy in men with prostate cancer. Bernie and Pearlman explore how traditional thinking is evolving, highlighting new data that supports continuing testosterone therapy even during prostate cancer diagnosis, surgery, and recovery—challenging long-held fears and offering patients better quality of life. Both stress the importance of early conversations with urologic and radiation oncologists to ensure shared decision-making that centers patient wellbeing.

The episode also delves into clomiphene use in men and its impact on lipid profiles. Bernie shares insights from her practice, explaining how routine lipid and hormone panels can uncover hidden cardiovascular risks in young men presenting for issues like erectile dysfunction or infertility. She underscores the need for a broader, more preventive approach to men's health, rather than simply treating isolated symptoms.

Finally, they discuss the real-world challenges of oral testosterone therapy. Bernie explains findings from a phase 3 study suggesting that starting at higher doses could minimize lab monitoring burdens, reduce treatment delays, and improve patient satisfaction — a critical point for busy clinicians managing testosterone therapy in large practices.

Relevant disclosures for Pearlman include Boston Scientific Corporation. Relevant disclosures for Bernie include Boston Scientific and Coloplast.

Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025. 

, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer. He also highlights the recent Northwestern-led course, “Enhancing Recruitment of Ethnic Minorities in Cancer Clinical Trials,” which took place on February 16, 2024. Murphy is a urologist at Northwestern University Feinberg School of Medicine in Chicago, Illinois.

During the discussion, Murphy provides some advice for researchers looking to increase diversity in their trials. He also references a study in which 64% of Black patients indicated that they would be willing to discuss clinical trials in prostate cancer, compared with 82% of White patients.

 While there is a difference, Murphy notes that the percentage of more than half of Black patients being willing to discuss clinical trials is not insignificant, and the data supports the idea of clinicians continuing to make the ask to their patients in order to help increase diversity in prostate cancer trials.

Murphy ends the discussion by sharing some of his thoughts on future work building on the Northwestern-led course, such as a session focused on mock recruitments with patients who have previously enrolled in clinical trials.

Don’t forget to subscribe to Speaking of Urology® on 

, or anywhere that podcasts are available.

1. Senft N, Hamel LM, Manning MA, et al. Willingness to discuss clinical trials among Black vs White men with prostate cancer. 

. 2020;6(11):1773-1777. doi:10.1001/jamaoncol.2020.3697

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

Dr. Murphy on increasing diversity in cancer clinical trials 

On an episode of Cleveland Clinic’s Cancer Advances podcast, host Dale Shepard, MD, PhD, talked with Zeyad Schwen, MD, about the use of focal therapy to treat patients with localized prostate cancer.

Schwen, who is a urologic oncologist at Cleveland Clinic, covers these topics:

The difference between traditional treatments and focal therapies

Factors that make a patient a good candidate for focal therapy

Focal procedures, including Nanoknife, high-intensity focused ultrasound and cryotherapy

Clinical trials devoted to focal therapies

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer. 

Dr. Schwen on focal therapies for prostate cancer

In this episode of Speaking of Urology®, 

, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection. Albala is the chief of urology at Crouse Hospital in Syracuse, New York, and Punnen is an associate professor of urologic oncology and an associate professor and vice chair of research at the Desai Sethi Urology Institute at the University of Miami in Florida.

This discussion originally took place during a live X (formerly Twitter) Spaces event held by Urology Times. In this exclusive interview, Albala and Punnen discussed the significance of advances such as liquid biopsies in prostate cancer, reviewed the current liquid biopsy tests available, and shared their own clinical experiences with the tests in their practice. They also highlighted data on the ExoDx prostate test from studies of clinical utility and validation studies.

Albala and Punnen ended their discussion by highlighting current education gaps surrounding the use of biomarker tests in practice and their predictions for the future of precision medicine.

In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.

Speaking of Urology: Liquid biopsy in prostate cancer 

 (NCT04384770), which compared Magnetic Resonance Imaging-guided stereotactic body radiotherapy with Computed Tomography-guided stereotactic body radiotherapy in localized prostate cancer. Kishan is an associate professor of radiation oncology and urology and the chief of genitourinary oncology for radiation oncology at University of California, Los Angeles. 

Don’t forget to subscribe to Speaking of Urology

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

Dr. Kishan highlights findings from the MIRAGE trial in prostate cancer

® spoke with Dr. Aaron Laviana, who discusses decisional regret in patients with prostate cancer. Laviana is an assistant professor of surgery and perioperative care and a courtesy faculty member of the department of oncology at The University of Texas at Austin Dell Medical School.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

Dr. Laviana on decisional regret after prostate cancer treatment

®Assistant Editor Janelle Hart spoke with 

. She discusses the findings of a recent 

 study, “Representation in Online Prostate Cancer Content Lacks Racial and Ethnic Diversity: Implications for Black and Latinx Men.” More specifically, she explains how these findings emphasize the need for content creators to focus more on equity, diversity, and inclusion when it comes to online medical literature. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine in New York City, New York.

“The current landscape of online materials about prostate cancer is generally pretty bleak,” says Stacy Loeb, MD, PhD, MSc.

Study finds lack of Black and Latinx representation in online prostate cancer literature

® Assistant Editor Janelle Hart spoke with 

 She discusses the role that high-intensity focused ultrasound (HIFU) has played among other minimally invasive and robotic technologies to mitigate the side effects and complications of treatment for prostate cancer, compared toe other treatment options. Linehan is an associate professor of urology and urologic oncology at the John Wayne Cancer Institute in Santa Monica, California.

“It's really become the epicenter of all the surgeries that we do in urology,” says Jennifer Linehan, MD.

Emerging HIFU technology shows promise in men with prostate cancer

 He discusses how even though there are stigmas surrounding active surveillance, a lot of research actually suggests that this form of care is preferred in patients with prostate cancer. Therefore, he emphasizes that this treatment method should be counseled accordingly by clinicians. Ehdaie is a urologic surgeon at the Memorial Sloan Kettering Cancer Center, New York City, New York.

“It doesn't need to be surgery or radiation. Setting that stage, really focusing on those conversations, using the appropriate tools that we've grasped from behavioral psychologists that are being used by negotiation specialists, are critical in medicine,” says Behfar Ehdaie, MD, MPH.

Destigmatizing Urology: Dr. Ehdaie discusses active surveillance

. She discusses the benefits of plant-based diets given the promising findings of the prospective study, “Association of plant-based diet index with prostate cancer risk,” published recently in the 

. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.

“We find that consuming more healthy, plant-based foods is associated with a lower risk of aggressive and lethal prostate cancer, and has many other health benefits, too,” says Stacy Loeb, MD, PhD, MSc.

Dr. Loeb on the association between plant-based diets and prostate cancer risk

"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

However, this regimen was associated with substantial toxicity, so careful patient selection is paramount, according to the authors.

Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer

In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors. 

Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

"As clinicians, researchers, and advocates, this moment invites us to reflect on how far we’ve come—and how much further we must go," writes Michael S. Cookson, MD, MMHC, FACS.

Prostate cancer awareness in 2025: A human imperative in the wake of President Biden’s diagnosis

In 2015, 1245 patients had prostate cancer and had also initiated a GLP-1 or GIP/GLP-1 receptor agonist compared with 69,808 patients in 2024. 

GLP-1 agonist use is rising in men with prostate cancer

In a recent interview, Rebecca A. Campbell, MD, a urologic oncology fellow at Cleveland Clinic in Cleveland, Ohio, discussed concrete steps to mitigate gender-based disparities in Altmetric Attention Scores (AAS) and citations within oncology, emphasizing the importance of awareness. She highlighted several strategies outlined in a recent paper to address these issues.

One key approach is to increase the representation of women on editorial boards of journals and as reviewers. This can help decrease cognitive bias and promote research authored by women, especially in prominent journals. Campbell noted that articles cited in high-impact journals often receive greater attention in news media and social platforms, leading to higher AAS. By increasing women's presence in these influential roles, the gap in both AAS and citation could potentially be closed.

Rebecca A. Campbell, MD, a urologic oncology fellow at Cleveland Clinic in Cleveland, Ohio, discussed concrete steps to mitigate gender-based disparities in Altmetric Attention Scores (AAS) and citations within oncology

Strategies to bridge gender disparities in AAS and citations in the oncology literature

Another significant step involves encouraging and promoting women researchers and physicians to lead large clinical trials. These trials tend to garner more media attention but are often led by men. Additionally, funding bodies should be urged to consider AAS and citation data within the context of existing biases when evaluating grant applications.

For health care professionals consuming oncology research, Campbell stressed the importance of being aware of these disparities. Although acknowledging the existence of gender gaps, she cautioned against evaluating the significance of an article based on the gender of its first or last author. The goal is to close the gender gap through systemic changes rather than individual bias in article interpretation.

1. Campbell RA, Helstrom E, Chew L, et al. Gender disparities in citations and Altmetric Attention Score in oncology. 

2025 Apr 10:OP2400767. doi:10.1200/OP-24-00767

Videos

One key approach is to increase the representation of women on editorial boards of journals and as reviewers.

In a recent interview, Stacy Loeb, MD, MSc, PhD (Hon), a professor in the departments of urology and population health at NYU Grossman School of Medicine and Perlmutter Cancer Center in New York, New York, discussed the complexities surrounding prostate-specific antigen (PSA) screening guidelines for older men, using President Joseph R. Biden’s case to illustrate potential limitations of current protocols. She explains that although guidelines recommend stopping routine PSA screening around age 70 or 75 years due to the increased risk of harm over benefit at a population level, individual cases like Biden’s raise important concerns. Stopping screening at 72 may have delayed the detection of an aggressive prostate cancer. However, she emphasizes that continued screening is not without risks, such as false positives, unnecessary biopsies, complications, and overtreatment. For example, a man could have a borderline PSA level, undergo a biopsy, experience severe adverse events, and still not have cancer—highlighting the potential harms of continued testing.

Loeb stressed the importance of individualized decision-making based on life expectancy and overall health rather than age alone. 

Stacy Loeb, MD, MSc, PhD (Hon), discusses the nuances of prostate cancer screening

Loeb stressed the importance of individualized decision-making based on life expectancy and overall health rather than age alone. She noted that some individuals in their 70s are remarkably healthy and active, with life expectancies that justify continued screening. She underscored the vast variability in aging and the need for personalized assessments. Moreover, she emphasized that patient preferences play a crucial role in screening decisions. Physicians should engage in shared decision-making, discussing the risks and benefits of screening and considering the patient’s values and concerns.

In summary, Loeb advocated for a more nuanced approach to PSA screening in older adults. Rather than applying age cut-offs rigidly, clinicians should consider individual health status, life expectancy, and personal preferences to guide decisions about prostate cancer screening.

Loeb stressed the importance of individualized decision-making based on life expectancy and overall health rather than age alone.

Selecting Between Receptor Pathway Inhibitors for mHSPC

Therapeutic Decision-Making in Advanced Prostate Cancer

Approach to selecting among multiple androgen receptor pathway inhibitors

Individualization of therapy based on patient factors

Consideration of drug-specific characteristics

Dr Shore provided guidance on approaching treatment decisions with multiple agents now available (enzalutamide, apalutamide, abiraterone, and darolutamide).

He emphasized the importance of individualizing therapy based on comorbidities, potential drug-drug interactions, convenience factors, and patient preferences.

The discussion noted darolutamide's lower central nervous system penetration and potentially improved tolerability in certain populations, while acknowledging that all these agents represent effective treatment options.

Explore the complexities of treatment options for metastatic hormone-sensitive prostate cancer, emphasizing shared decision-making and patient considerations.

Video Series

Investigator Perspectives

The Use of Ultra-Low PSA in Specific Patient Profiles

Patient Selection for Ultra-Low PSA Monitoring

Identification of patient profiles most likely to benefit from ultra-low PSA monitoring

Potential applications in high-volume disease or triplet therapy

Dr Shore identified specific patient profiles or risk categories where the ultra-low PSA threshold might be particularly valuable.

He discussed its potential relevance for patients with high-volume disease, those receiving triplet therapy, or patients demonstrating rapid initial PSA declines.

Research explores the effectiveness of Aerote in treating metastatic hormone-sensitive prostate cancer, focusing on patient subgroups and genetic factors.

On June 3, 2025, the FDA approved darolutamide (Nubeqa) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).

 Darolutamide was previously approved in the US for mCSPC in combination with docetaxel.

, discusses the implications of this expanded approval for clinical practice.

He noted, “Having as many options as possible is critically important for both us that are treating these patients, but also for patients, getting them involved in the decision making [and] addressing the realities of what other drugs they're taking.”

“I think the big take-home message is now we've got multiple, multiple drugs showing that we can do significantly better than ADT alone," says Fred Saad, MD, FRCS. 

Prostate Cancer

Latest News